Retrophin, Inc. (RTRX) Lifted to Hold at ValuEngine

Retrophin, Inc. (NASDAQ:RTRX) was upgraded by research analysts at ValuEngine from a “sell” rating to a “hold” rating in a note issued to investors on Friday, August 4th.

A number of other analysts also recently issued reports on RTRX. TheStreet raised shares of Retrophin from a “d” rating to a “c-” rating in a report on Friday, May 12th. William Blair reissued an “outperform” rating on shares of Retrophin in a report on Thursday, April 6th. Finally, Zacks Investment Research downgraded shares of Retrophin from a “strong-buy” rating to a “hold” rating in a report on Wednesday, May 3rd. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $32.25.

Retrophin (NASDAQ:RTRX) traded up 0.93% during trading on Friday, reaching $23.86. 416,535 shares of the company were exchanged. The company’s 50-day moving average price is $20.41 and its 200-day moving average price is $19.18. The stock’s market capitalization is $915.87 million. Retrophin has a 1-year low of $15.55 and a 1-year high of $24.57.

Retrophin (NASDAQ:RTRX) last announced its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.24) by $0.10. Retrophin had a negative return on equity of 7.31% and a negative net margin of 48.74%. The firm had revenue of $38.80 million for the quarter, compared to analysts’ expectations of $37.36 million. During the same period last year, the company posted $0.07 earnings per share. The business’s quarterly revenue was up 16.5% on a year-over-year basis. On average, equities analysts forecast that Retrophin will post ($1.13) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by Community Financial News and is owned by of Community Financial News. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The original version of this news story can be accessed at https://www.com-unik.info/2017/08/18/retrophin-inc-rtrx-upgraded-to-hold-at-valuengine-updated.html.

In other news, COO Neil F. Mcfarlane sold 1,378 shares of the stock in a transaction dated Wednesday, August 16th. The shares were sold at an average price of $22.50, for a total value of $31,005.00. Following the completion of the sale, the chief operating officer now directly owns 13,622 shares in the company, valued at $306,495. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 2.41% of the company’s stock.

Several large investors have recently modified their holdings of the stock. Weiss Multi Strategy Advisers LLC acquired a new stake in shares of Retrophin during the first quarter worth approximately $185,000. Point72 Asset Management L.P. boosted its stake in shares of Retrophin by 133.8% in the first quarter. Point72 Asset Management L.P. now owns 964,800 shares of the biopharmaceutical company’s stock worth $17,810,000 after buying an additional 552,065 shares during the period. Virginia Retirement Systems ET AL boosted its stake in shares of Retrophin by 99.2% in the first quarter. Virginia Retirement Systems ET AL now owns 75,100 shares of the biopharmaceutical company’s stock worth $1,386,000 after buying an additional 37,400 shares during the period. FMR LLC boosted its stake in shares of Retrophin by 24.8% in the first quarter. FMR LLC now owns 1,958,875 shares of the biopharmaceutical company’s stock worth $36,161,000 after buying an additional 389,714 shares during the period. Finally, Russell Investments Group Ltd. acquired a new stake in shares of Retrophin during the fourth quarter worth approximately $387,000.

About Retrophin

Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).

To view ValuEngine’s full report, visit ValuEngine’s official website.

What are top analysts saying about Retrophin Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Retrophin Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit